biostudies-literatureUnknown13(11)Hsu WH<h4>Purpose</h4>To estimate differences in pain control between patients with cancer and with or without dementia during terminal cancer stages 3 months or 1 month before cancer death.<h4>Patients and methods</h4>We conducted frequency matching cohort for age, sex, and year of death for both groups at a 1:4 ratio. The prescription prevalence, total cumulative dose, and average daily dose of opioids during the terminal cancer stages 3 months and 1 month before cancer death were estimated.<h4>Results</h4>Patients with cancer and dementia were prescribed lower amounts of opioids 3 months before death (57.5% vs. 73.9%, respectively; adjusted odds ratio [OR] 0.46; 95% confidence interval [CI] 0.44-0.49) and 1 month before death (54.4% vs. 70.3%, respectively; adjusted OR 0.50; 95% CI 0.47-0.53). The total cumulative dose of opioids (mg) was lower in patients with cancer and dementia 3 and 1 month(s) before death (3 months: 1,578 mg vs. 2,666 mg, respectively; β=-1,125.9, <i>P</i><0.001; 1 month: 921 mg vs. 1,533 mg, respectively; β=-622.1, <i>P</i><0.001). The average daily opioid dose (mg/day), patients with cancer and dementia received a lower dose 3 months before death (31 mg vs. 48 mg; β=-22.6, <i>P</i><0.001) and 1 month before death (38 mg vs. 60 mg; β=-17.1, <i>P</i><0.001).<h4>Conclusion</h4>The prevalence of opioid prescription was significantly lower in patients with both cancer and dementia during their terminal cancer stages 3 months and 1 month before death.American journal of translational research13034-13042https://www.ebi.ac.uk/biostudies/studies/S-EPMC8661160biostudies-literatureInsufficient pain control for patients with cancer and dementia during terminal cancer stages.PMC8661160Hsu WHHsieh JGLin HRWu SYWang YWHsieh CJfalseInsufficient pain control for patients with cancer and dementia during terminal cancer stages.<h4>Purpose</h4>To estimate differences in pain control between patients with cancer and with or without dementia during terminal cancer stages 3 months or 1 month before cancer death.<h4>Patients and methods</h4>We conducted frequency matching cohort for age, sex, and year of death for both groups at a 1:4 ratio. The prescription prevalence, total cumulative dose, and average daily dose of opioids during the terminal cancer stages 3 months and 1 month before cancer death were estimated.<h4>Results</h4>Patients with cancer and dementia were prescribed lower amounts of opioids 3 months before death (57.5% vs. 73.9%, respectively; adjusted odds ratio [OR] 0.46; 95% confidence interval [CI] 0.44-0.49) and 1 month before death (54.4% vs. 70.3%, respectively; adjusted OR 0.50; 95% CI 0.47-0.53). The total cumulative dose of opioids (mg) was lower in patients with cancer and dementia 3 and 1 month(s) before death (3 months: 1,578 mg vs. 2,666 mg, respectively; β=-1,125.9, <i>P</i><0.001; 1 month: 921 mg vs. 1,533 mg, respectively; β=-622.1, <i>P</i><0.001). The average daily opioid dose (mg/day), patients with cancer and dementia received a lower dose 3 months before death (31 mg vs. 48 mg; β=-22.6, <i>P</i><0.001) and 1 month before death (38 mg vs. 60 mg; β=-17.1, <i>P</i><0.001).<h4>Conclusion</h4>The prevalence of opioid prescription was significantly lower in patients with both cancer and dementia during their terminal cancer stages 3 months and 1 month before death.2021-01-01T00:00:00Z20212024-02-15T00:05:52.181Z2022-02-11T13:49:54.329ZS-EPMC866116034956521